Search alternatives:
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
e fold » _ fold (Expand Search), 5 fold (Expand Search), 2 fold (Expand Search)
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
e fold » _ fold (Expand Search), 5 fold (Expand Search), 2 fold (Expand Search)
-
19761
-
19762
-
19763
-
19764
-
19765
Tumor Cells Switch to Mitochondrial Oxidative Phosphorylation under Radiation via mTOR-Mediated Hexokinase II Inhibition - A Warburg-Reversing Effect
Published 2015“…Three tumor cell lines (breast cancer MCF-7, colon cancer HCT116 and glioblastoma U87) showed a quick relocation of mTOR to mitochondria after irradiation with a single dose 5 Gy, which was companied with decreased lactate production, increased mitochondrial ATP generation and oxygen consumption. …”
-
19766
-
19767
Conformational characterization of a novel anti-HER2 candidate antibody
Published 2019“…In this work, the conformational features of a novel monoclonal antibody (called 5G4) were evaluated by means of circular dichroism spectroscopy and fluorescence. …”
-
19768
-
19769
<em>In Vitro</em> and <em>Ex Vivo</em> Analysis of <em>CHRNA3</em> and <em>CHRNA5</em> Haplotype Expression
Published 2011“…For <em>in vitro</em> analyses, promoter haplotypes were sub-cloned into a luciferase reporter vector. When assessed in BE(2)-C cells, luciferase expression was equivalent among <em>CHRNA3</em> haplotypes, but the combination of deletion at rs3841324 and variation at rs503464 decreased <em>CHRNA5</em> promoter-derived luciferase activity, possibly due to loss of an SP-1 and other site(s). …”
-
19770
-
19771
-
19772
Effects of a clinical medication review focused on personal goals, quality of life, and health problems in older persons with polypharmacy: A randomised controlled trial (DREAMeR-s...
Published 2019“…Over 6 months, in the intervention group, HR-QoL measured with EQ-VAS increased by 3.4 points (95% confidence interval [CI] 0.94 to 5.8; <i>p</i> = 0.006), and the number of health problems with impact on daily life decreased by 12% (difference at 6 months −0.34; 95% CI −0.62 to −0.044; <i>p</i> = 0.024) as compared with the control group. …”
-
19773
Overexpression of tau inhibited whole-cell currents through Kv channels.
Published 2015“…<p>(A) The outward Kv currents were evoked by stepped up to +60 mV for 500 ms at a holding potential of -80 mV in N2A cells. …”
-
19774
-
19775
-
19776
-
19777
Changes in ELF5, FOXA1 and ER binding to the genome are reflected in gene expression.
Published 2020“…Panel <b>B</b>, as for panel A but showing genes for which FOXA1 or ER binding was increased or decreased by induction of ELF5. …”
-
19778
PRMT5 isoforms during zebrafish developmental stages
Published 2024“…Q503E3). Mobility of Prmt5 at 72 hpf indicated a lower apparent molecular weight compared to the 24 hpf zebrafish Prmt5 variant 1. …”
-
19779
ELF5 transcriptional effects measured by RNA-seq.
Published 2020“…<p>Panel <b>A</b>, GO ontologies enriched in the RNA-seq data set by induction of ELF5, font size relative to enrichment score. …”
-
19780
The MITF-SOX10 regulated long non-coding RNA DIRC3 is a melanoma tumour suppressor
Published 2019“…<i>DIRC3</i> is a nuclear lncRNA that activates expression of its neighbouring <i>IGFBP5</i> tumour suppressor through modulating chromatin structure and suppressing SOX10 binding to putative regulatory elements within the <i>DIRC3</i> locus. …”